
Imbria Presents Positive Clinical Data from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic ...
– Ninerafaxstat improves cardiac energetics, cardiac reserve capacity, 6-minute walk distance and heart failure-related health status (KCCQ) in cardiometabolic HFpEF – – Findings support further development of ninerafaxstat in HFpEF and adjacent CV …